
James Buteau
@buteaujames
PhD candidate, PSMA theranostics, nuclear medicine consultant, Peter Mac
ID: 1240406717722062849
18-03-2020 22:36:37
600 Tweet
501 Followers
311 Following

Michael Hofman presents at 2025 PSMA & Beyond Conference UCLA UC San Francisco Prostate Cancer Foundation ... Impressive attendance! Thanks to organisers: Thomas Hope Jeremie Calais Johannes Czernin UroToday.com Don't miss our next webinar: Link.prostic.org/webinar


Our webinars are back! Join us in Unravelling PSMA Biology on April 23/24 with Michael Hofman, PCF Science, GU Cast | Urology podcast! and our special guest speakers: Misha Beltran, Louise Emmett, Edmond Kwan & Martin Pomper, MD PhD š¬ Live, interactive and FREEā¼ļø Register now: link.prostic.org/webinar


We are seeking a clinical trial co-ordinator who wants to make a true impact... at Peter Mac Cancer Centre . youāll lead the coordination of our ProsTIC clinical trials, building on more than a decade of global leadership in cutting-edge research. Why Join Us? ⦿ Global Recognition: We



I hope the 2025 Eric Susman Prize inspires many many people to explore a career in nuclear medicineāa fascinating and rapidly evolving internal medicine specialty of the The Royal Australasian College of Physicians, still relatively under the radar. There's never been a more exciting time to be part of this field.

Unravelling PSMA Biology - 2025 ProsTIC PCF Global Webinar youtu.be/0j1MBJkXjGI?fe⦠via YouTube 900 registrants from 69 countries !! Incredible speakers.Misha Beltran Louise Emmett Edmond Kwan Martin Pomper, MD PhD Hosts. Declan Murphy Howard Soule Andrea Miyahira



ā¶āøGa-NeoB PET/CT has diagnostic potential in the staging of ER/PR-positive and HER2-negative breast cancer. Learn more: ow.ly/NJVA50VuLRT #NuclearMedicine #BreastCancer #PETscan Zahra Sabahi Louise Emmett Cindy Mak


Stunning research from Edmond Kwan on ctDNA in theranostics: š§¬Low ctDNA predicts better response with ¹ā·ā·Lu-PSMA-617 vs. cabazitaxel chemotherapy ā ļøPTEN alterations linked to worse outcomes on cabazitaxel š§ŖATM defects tied to favorable PSMA-617 results š©»PET quantitative







š„³ Today, we randomised the final patient on Trans Tasman Radiation Oncology Group 19.06 DECREASE trial! This trial randomised patients with prostate cancer who were becoming resistant to hormone therapy, without evidence of metastases on bone or CT scan, to Darolutamide +/- Stereotactic


620 of 660 patients randomised in #PRIMARY2 šÆBringing PSMA PET from staging to DIAGNOSIS šThe finishing line approaches Thank-youāinvestigators James Buteau Louise Emmett Daniel Moon Declan Murphy + many more Supported by Peter Mac Cancer Centre @SVHSydney PCF Science ProsTIC


#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in The Lancet Oncology : thelancet.com/journals/lanon⦠š£ 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) š£Very few
